NexImmune Inc Sustainability Reports
NexImmune, Inc. is a clinical-stage biotechnology company developing antigen-directed immunotherapies. The company's proprietary Artificial Immune Modulation (AIM) nanotechnology platform orchestrates targeted T cell responses to treat cancer and autoimmune diseases.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 5493005RDYAV26LAQ930
FIGI: BBG007SK6379
1 reports from 2021 to 2021
